CollPlant Biotechnologies (CLGN) on Thursday filed a prospectus registering up to 31 million ordinary shares for potential resale by investors who participated in its July 6 private placement.
The shares include those issued directly in the deal, along with shares tied to pre-funded warrants, Series A and Series B warrants, and warrants held by placement agent H.C. Wainwright, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.